Subscribe to our News Updates & Alerts

ASX AGN: A$

Home
About
Investors
Technology
Media
- News & Media
Contact

ASX Announcements

2022
2021

19 May 2022Successful Completion of Final Pre-Clinical PK Study
05 May 2022GLP Safety Studies Successfully Completed
29 Apr 2022Quarterly Activities/Appendix 4C Cash Flow Report
26 Apr 2022Maximum Tolerated Dose Successfully Established in Studies
04 Apr 2022Initial Director's Interest Notice
04 Apr 2022Argenica Appoints CEO Dr Liz Dallimore Managing Director
30 Mar 2022Positive Preclincal Data on Efficacy in New Indication
21 Mar 2022Peer Reviewed Paper Published on Preclinical Study
16 Mar 2022Investor Presentation
28 Feb 2022Change of Director's Interest Notice
24 Feb 2022Successful Completion of Final GLP Genotoxicity Studies
22 Feb 2022Half Yearly Report and Accounts
27 Jan 2022Quarterly Activities/Appendix 4C Cash Flow Report
24 Jan 2022Preliminary Pre-Clinical Tox Studies Successfully Completed
13 Jan 2022Argenica Appoints Head of Clinical Development
13 Jan 2022Notification regarding unquoted securities - AGN

31 Dec 2021Application for quotation of securities - AGN
17 Dec 2021Application for quotation of securities - AGN
10 Dec 2021Release of Restricted Securities from Escrow
09 Dec 2021Argenica to be Granted Patent Protection in the US
17 Nov 2021Results of Annual General Meeting
17 Nov 2021AGM Presentation
03 Nov 2021Positive Preclinical Data for ARG-007 Neuroprotection in HIE
28 Oct 2021Quarterly Activities/Appendix 4C Cash Flow Report
27 Oct 2021Investor Presentation
18 Oct 2021Phase 1 Clinical Trial Overview & Roadmap
15 Oct 2021Notice of Annual General Meeting/Proxy Form
14 Oct 2021Application for quotation of securities - AGN
04 Oct 2021Release of Restricted Securities from Escrow
30 Sep 2021Argenica Partners With Linear For Phase 1 Clinical Trial
21 Sep 2021Date of AGM & Closing Date for Director Nominations
14 Sep 2021Argenica Achieves Manufacturing Milestones
27 Aug 2021Appendix 4G & Corporate Governance Statement
27 Aug 2021Appendix 4E & Annual Report 30 June 2021
11 Aug 2021Appendix 3G
05 Aug 2021Proposed issue of securities - AGN
05 Aug 2021Issue of Options
29 Jul 2021Quarterly Activities/Appendix 4C Cash Flow Report
21 Jul 2021Grant Secured to Advance Pre-Clinical Studies Of ARG-007
13 Jul 2021Study Additional Information
12 Jul 2021Study Shows ARG-007 Does Not Degrade
01 Jul 2021Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study
30 Jun 2021Change of Registered Office
16 Jun 2021Investor Presentation
11 Jun 2021Argenica Commences Trading on ASX
09 Jun 2021Becoming a substantial holder
09 Jun 2021Becoming a substantial holder
09 Jun 2021Initial Director's Interest Notice x4
09 Jun 2021Confirmation Statements
09 Jun 2021Top 20 Holders
09 Jun 2021Distribution Schedule
09 Jun 2021Securities Trading Policy
09 Jun 2021Corporate Governance Statement
09 Jun 2021Employee Securities Incentive Plan
09 Jun 2021Interim Report for the period ended 31 December 2020
09 Jun 2021Annual Report for period from incorporation to 30 June 2020
09 Jun 2021Constitution
09 Jun 2021Prospectus
09 Jun 2021Appendix 1A & Information Form and Checklist
09 Jun 2021ASX Notice - Admission to Official List

ASX Announcements

Subscribe to our mailing list to stay up to date with Argenica Therapeutics

First Name*
Last Name*
Email*

Argenica Therapeutics Limited
4/117 Broadway
Nedlands WA 6009, Australia
PO Box 1458, West Perth WA 6872

Ph: 08 9329 3396

info@argenica.com.au

Home
About
Investors
Media
- News & Media
- Presentations
Contact Us

The Science
Development

© Copyright 2022 Argenica Therapeutics Pty Ltd Privacy Policy Terms & Conditions

Website by Crux Creative and Meta Creative

Home
About
Investors
Technology
Media
- News & Media
Contact

Privacy Policy
Terms & Conditions